Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 6, 2004, Pages 625-634

  Narayan, Sangeeta ^a   Hay, Joel ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amphetamine dextroamphetamine mixed salts; Attention deficit hyperactivity disorder; Cost effectiveness; Methylphenidate

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; DRUG WITHDRAWAL; GROWTH RETARDATION; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INSOMNIA; MEDICAL DECISION MAKING; META ANALYSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SCHOOL HEALTH SERVICE; SIDE EFFECT; STOMACH DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 9944247045     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.6.625     Document Type: Review

References (41)

1. Robison LM, Sclar DA, Dkaer TL. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Ped. 38(4), 209-217 (1999).
2. Rowland AS, Umbach DM, Stallon L. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am. J. Public Health 92(2), 231-234 (2002).
3. AACAP Official Action. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Psych. 36(Suppl. 10), 85-121 (1997).
4. American Academy of Pediatrics. Committee on quality improvement, subcommittee on attention-deficit/hyperactivity disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105(5), 1158-1170 (2000).
5. Kelleher KJ, Childs GE, Harman JS. Healthcare costs for children with attention-deficit/hyperactivity disorder. TEN 3(4), 60-63 (2001).
6. Attention deficit disorder and learning disability, United States, 1997-1998. CDC Vital and health statistics. 10, 206 (2002).
7. Perrin JM, Stein MT, Amler RW. Clinical Practice Guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108(4), 1-20 (2001).
8. Pliszka SR, Greenhill LL, Crismon ML. The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics. J. Am. Acad. Child. Adolesc. Psych. 39(7), 920-927 (2000).
9. Elia J, Borcherding BG, Rapoprt JL. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 36, 141-155 (1991).
10. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N. Engl. J. Med. (340)1, 40-46 (1999).
11. Spencer TJ, Biederman J, Wilens TE. Novel treatments for attention-deficit/hyperactivity disorder in children. J. Clin. Psych. 63(Suppl. 12) 16-22 (2002).
12. Milne R, Stein K. Methylphenidate in children with hyperactivity. Wessex Institute Development and Evaluation Committee Report. 78 (1998).
13. Conners CK, Epstein JN, March JS. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J. Am. Acad. Child. Adolesc. Psych. 40(2), 159-167 (2001).
14. Leibson CL, Katusic SK, Barbaresi WJ. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 285(1), 53-66 (2001).
15. Chan E, Zhan C, Homer CJ. Healthcare use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. 156, 504-511 (2002).
16. Marchetti A, Magar R, Lau H. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin. Ther. 23(11), 1904-1920 (2001).
17. Pliszka SR, Browne RG, Olvera RL. A double-blind, placebo-controlled study of adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psych. 39(5), 1-12 (2000).
18. Pelham WE, Gnagy E, Chronis A. A comparison of morning-only and morning/late afternoon adderall to moring-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104(6), 1300-1311 (1999).
19. Pelham WE, Aronoff HR, Midlam JK. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103(4), 1-14 (1999).
20. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch. Pediatr. Adolesc. Med. 156, 384-391 (2002).
21. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol. Drug Safety 10, 85-94 (2001).
22. Guevara J, Lozano P, Wickizer T. Utilization and cost of healthcare services for children with attention-deficit/hyperactivity disorder. Pediatrics 108(1), 71-78 (2001).
23. Swensen AR, Birnbaum HG, Secnik K et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J. Am. Acad. Child. Adolesc. Psych. 42(12), 1415-1423 (2003).
24. Gillberg C, Melander H, von Knorring AL. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch. Gen. Psych. 54(9), 857-864 (1997).
25. Pelham WE, Gnagy EM, Burrows A. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6), 1-28 (2001).
26. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psych. 36(12), 1715-1725 (2001).
27. Pelham WE, Carlson C, Sams SE. Separate and combined effects of methylphenidate and behavior modification on the classroom behavior and academic performance of ADHD boys: group effects and individual differences. J. Consult. Clin. Psychol. 61, 506-515 (1993).
28. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psych. 63(Suppl. 12), 10-15 (2002).
29. Grcevich S, Rowane WA, Marcellino B. Retrospective comparison of adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 11(1) 35-41 (2001).
30. Millor A, Lee SK, Raina P. A review of therapies for attention-deficit/hyperactivity disorder. Report by the Canadian coordinating office of health technology assessment (CCOHTA). RFP#ADHD-1196 (1998).
31. Lord J, Paisley S. The clinical effectiveness and cost effectiveness of methylphenidate for hyperactivity in childhood. Report by National Institute for Clinical Excellence, London, UK (2000).
32. Wilens T, Pelham W, Stein M. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J. Am. Acad. Child. Adolesc. Psych. 42(4), 424-433 (2002).
33. Sawyer MG, Whaites L, Rey JM. Health-related quality of life of children and adolescents with mental disorders. J. Am. Acad. Child. Adolesc. Psych. 41(5), 530-537 (2003).
34. First Databank. Price Probe. Updated May 7, 2003 (2003).
35. Biederman J, Lopez FA, Boellner SW. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (AdderallXR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110(2), 258-266 (2002).
36. James RS, Sharp WS, Bastain TM. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J. Am. Acad. Adolesc. Psych. 40(11), 1268-1276 (2001).
37. Spencer T, Biederman J, Wilens T. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psych. 58(8), 775-782 (2001).
38. Wolraich MI, Greenhill LL, Pelham W. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108(4), 883-892 (2001).
39. Klein RG, Wender P. The role of methylphenidate in psychiatry. Arch. Gen. Psych. 52(6), 429-433 (1995).
40. The MTA Co-operativc Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psych. 56(12), 1073-1086 (1999).
41. Golinko BE. Side effects of dextroamphetamine and methylphenidate in hyperactive children - a brief review. Prog. Neuro-Psychopharmacol. Biol. Psych. (8), 1-8 (1984).